Apollo Medical Holdings Inc (NASDAQ:AMEH) Given $23.00 Consensus Target Price by Analysts

Shares of Apollo Medical Holdings Inc (NASDAQ:AMEH) have been assigned an average broker rating score of 2.00 (Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy rating.

Brokerages have set a one year consensus target price of $23.00 for the company and are anticipating that the company will post $0.04 EPS for the current quarter, according to Zacks. Zacks has also assigned Apollo Medical an industry rank of 60 out of 254 based on the ratings given to its competitors.

Several equities research analysts have commented on AMEH shares. TheStreet raised shares of Apollo Medical from a “d+” rating to a “c-” rating in a report on Tuesday. ValuEngine downgraded shares of Apollo Medical from a “buy” rating to a “hold” rating in a report on Thursday. BidaskClub raised shares of Apollo Medical from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, Zacks Investment Research raised shares of Apollo Medical from a “strong sell” rating to a “hold” rating in a report on Monday, May 18th.

NASDAQ AMEH traded down $0.38 during trading on Friday, hitting $17.16. 67,767 shares of the company’s stock traded hands, compared to its average volume of 47,678. The stock has a market capitalization of $926.11 million, a price-to-earnings ratio of 46.38, a PEG ratio of 5.85 and a beta of 0.33. Apollo Medical has a 12-month low of $9.27 and a 12-month high of $23.26. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.12 and a current ratio of 3.12. The business has a 50 day moving average of $14.75 and a 200-day moving average of $16.31.

Apollo Medical (NASDAQ:AMEH) last released its quarterly earnings data on Thursday, March 12th. The company reported $0.18 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.20 by ($0.02). The business had revenue of $178.75 million for the quarter. Apollo Medical had a net margin of 2.52% and a return on equity of 8.34%. On average, analysts expect that Apollo Medical will post 0.75 EPS for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Great West Life Assurance Co. Can bought a new position in shares of Apollo Medical during the 4th quarter valued at approximately $29,000. Citigroup Inc. increased its position in shares of Apollo Medical by 51.8% during the 4th quarter. Citigroup Inc. now owns 2,059 shares of the company’s stock valued at $38,000 after purchasing an additional 703 shares during the last quarter. BNP Paribas Arbitrage SA grew its position in Apollo Medical by 159.9% in the 1st quarter. BNP Paribas Arbitrage SA now owns 2,557 shares of the company’s stock valued at $33,000 after acquiring an additional 1,573 shares during the last quarter. Tower Research Capital LLC TRC bought a new position in Apollo Medical in the 4th quarter valued at $76,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Apollo Medical during the 4th quarter worth $83,000. Institutional investors own 6.76% of the company’s stock.

About Apollo Medical

Apollo Medical Holdings, Inc, a physician-centric integrated population health management company, provides medical care services. The company offers care coordination services to principal constituents of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.

Featured Story: Stock Selection – What is cash flow?

Get a free copy of the Zacks research report on Apollo Medical (AMEH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Apollo Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Medical and related companies with MarketBeat.com's FREE daily email newsletter.